Robin Frye
Impact in
- Dermatology top 1%
- Cutaneous lymphoproliferative disorders research
-
- Lymphoma Diagnosis and Treatment
Papers in
-
- Histone Deacetylase Inhibitors Research 15
- Protein Degradation and Inhibitors 6
- Ubiquitin and proteasome pathways 5
- Phytochemical compounds biological activities 3
-
- Lymphoma Diagnosis and Treatment 7
- Co-authors
- Richard Piekarz (18 shared papers)Susan E. Bates (16 shared papers)William D. Figg (7 shared papers)Erin R. Gardner (5 shared papers)Steven L. Allen (11 shared papers)Maria L. Turner (8 shared papers)Seth M. Steinberg (5 shared papers)Mark Kirschbaum (9 shared papers)
- Journals
- Blood (6 papers)Journal of Clinical Oncology (5 papers)Clinical Cancer Research (3 papers)Expert Review of Anticancer Therapy (1 paper)British Journal of Haematology (1 paper)
- Partner nations
- United StatesAustraliaItaly
In The Last Decade
Robin Frye
19 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 81
- Dermatology 362
- Pathology and Forensic Medicine 441
- Oncology 474
- Molecular Biology 1.1k
- Immunology 329
Countries citing papers authored by Robin Frye
This map shows the geographic impact of Robin Frye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Frye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Frye more than expected).
Fields of papers citing papers by Robin Frye
This network shows the impact of papers produced by Robin Frye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Frye. The network helps show where Robin Frye may publish in the future.
Co-authors
The 25 scholars most cited alongside Robin Frye, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma Hit paper breakdown → | 2009 | 561 |
| 2 | 2011 | 359 | |
| 3 | 2010 | 224 | |
| 4 | 2004 | 74 | |
| 5 | 2009 | 64 | |
| 6 | 2013 | 57 | |
| 7 | 2009 | 53 | |
| 8 | 2012 | 45 | |
| 9 | 2008 | 31 | |
| 10 | 2007 | 28 | |
| 11 | 2012 | 26 | |
| 12 | 2005 | 17 | |
| 13 | 2008 | 16 | |
| 14 | 2005 | 13 | |
| 15 | 2009 | 11 | |
| 16 | 2004 | 9 | |
| 17 | 2006 | 7 | |
| 18 | 2004 | 6 | |
| 19 | Pharmacokinetic and biomarker analysis in a phase II trial of the HDAC inhibitor romidepsin, FK228 | 2008 | 1 |
About Robin Frye
Robin Frye is a scholar working on Molecular Biology, Pathology and Forensic Medicine, Dermatology, Oncology and Immunology, having authored 19 papers that have together received 1.6k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (15 papers), Lymphoma Diagnosis and Treatment (7 papers), Cutaneous lymphoproliferative disorders research (7 papers), Protein Degradation and Inhibitors (6 papers), Ubiquitin and proteasome pathways (5 papers), Peptidase Inhibition and Analysis (5 papers), T-cell and Retrovirus Studies (4 papers) and Phytochemical compounds biological activities (3 papers). The work is most often cited by research in Dermatology (362 citations), Pathology and Forensic Medicine (441 citations), Oncology (474 citations), Molecular Biology (1.1k citations) and Immunology (329 citations). Robin Frye has collaborated with scholars based in United States, Australia and Italy. Frequent co-authors include Richard Piekarz, Susan E. Bates, William D. Figg, Erin R. Gardner, Steven L. Allen, Maria L. Turner, Seth M. Steinberg, Mark Kirschbaum, Jasmine Zain and David Joske. Their work appears in journals such as Blood, Journal of Clinical Oncology, Clinical Cancer Research, Expert Review of Anticancer Therapy and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.